Lung Cancer

Roy S. Herbst, MD, PhD, helped usher in the age of targeted therapy and immunotherapy in lung cancer, turning an almost hopeless disease into a condition that can be treated and even cured.

Closing their discussion, the panel shares where they think the NSCLC treatment landscape will be in the future, and what to look forward to.

In combination with standard-of-care carboplatin and pemetrexed, the investigational agent LP-300 will be evaluated in never smokers with non–small cell lung cancer in the phase 2 HARMONIC study.

The median time between pathologic diagnosis to next-generation sequencing was reduced in a quality improvement project for patients with newly diagnosed metastatic non–small cell lung cancer.

The FDA has granted an orphan drug designation to vebreltinib for the treatment of patients with non–small cell lung cancer harboring MET genomic tumor aberrations.

The United Kingdom’s National Institute for Health and Care Excellence has issued final guidance recommending the use of mobocertinib for patients with advanced non–small cell lung cancer harboring EGFR exon 20 insertion mutations who have already received platinum-based chemotherapy.

The Center for Drug Evaluation of the China National Medical Products Administration has granted a breakthrough therapy designation to ivonescimab plus docetaxel for patients with locally advanced or metastatic non–small cell lung cancer who failed to respond to a prior PD-(L)1 inhibitor plus platinum-based doublet chemotherapy.

The panel explains their approaches to treating patients with mutated NSCLC with immunotherapy.

Dr Johnson reviews data from the ARC-7 trial investigating an anti-PD-L1 plus anti-TGIT combination treatment for advanced NSCLC.

Balazs Halmos, MD, discusses the importance of testing for HER2 mutations and exon 20 insertions, which are emerging new targets in non–small cell lung cancer, and how fam-trastuzumab deruxtecan-nxki meets needs for patients with HER2-mutant disease.

Mark G. Kris, MD, discusses the role of immunotherapy in patients with non–small cell lung cancer without driver mutations.

In treating patients with locally advanced non–small cell lung cancer, one must consider multiple factors when deciding whether to treat them with immunotherapy or a targeted approach, even though the optimal treatment sequence has yet to be definitively established.

Osimertinib remains the preferred first-line therapy for patients with EGFR-mutated non–small cell lung cancer. However, for those with classic EGFR mutations, the day is fast approaching when physicians will add chemotherapy to first-line treatment with the EGFR TKI based on ctDNA results.

Investigators are harnessing comprehensive molecular profiling to detect new targets, optimize existing treatment regimens, and develop novel therapies for patients with EGFR and MET exon 20–insertion positive non–small cell lung cancer.

CYNK-101 demonstrated synergistic activity when used in combination with avelumab through antibody-dependent cellular cytotoxicity against PD-L1–positive non–small cell lung cancer, triple-negative breast cancer, and bladder cancer cell lines, according to preclinical data.

Benjamin Philip Levy, MD, discusses potential future uses for atezolizumab in non–small cell lung cancer.

The first-line combination of pembrolizumab and eftilagimod alpha elicited a 40.4% (95% CI, 31.3%-50.0%) overall response rate by immune RECIST criteria in the intent-to-treat population in patients with advanced non–small cell lung cancer, according to updated findings from the phase 2 TACTI-002 trial.

Balazs Halmos, MD, discusses the significance of the FDA approval of tremelimumab-actl plus durvalumab and chemotherapy in patients with metastatic non–small cell lung cancer.

Mark G. Kris, MD, discusses the role of atezolizumab in patients with non–small cell lung cancer.

The FDA has approved tremelimumab-actl (Imjudo) plus durvalumab (Imfinzi) and platinum-based chemotherapy for adult patients with metastatic non–small cell lung cancer without sensitizing EGFR mutation or ALK aberrations.

The panel closes by highlighting unmet needs in molecular testing, and advances they are looking forward to.

Drs Morganstein and Ramkumar detail the financial considerations patients and physicians face during the process of molecular testing for NSCLC.

Drs Peters and Velcheti provide an overview of the role of anti-TGIT immunotherapies in NSCLC treatment.

Solange Peters, MD, explains the currently available treatment options for patients with advanced NSCLC after progression on immunotherapy.

The panel shares the data that excited them the most from ESMO 2022, and what to look forward to in the future.

The FDA has approved cemiplimab-rwlc (Libtayo) in combination with platinum-based chemotherapy in adult patients with advanced non–small cell lung cancer with no EGFR, ALK, or ROS1 aberrations.

Data presented at the ESMO Congress 2022 highlighted advances across treatment modalities, including landmark data for trials in melanoma, breast cancer, and lung cancer, as well as early data that made headlines in a subgroup of patients with colon cancer.

Five-year follow-up data from the phase 3 KEYNOTE-189 trial further confirms the use of first-line pembrolizumab in combination with pemetrexed and platinum improves long-term survival outcomes for patients with treatment-naïve, metastatic, nonsquamous non–small cell lung cancer.

On September 8, 2022, OncLive® brought together physicians who treat FL to participate in a virtual workshop and discuss the treatment landscape and management of patients with relapsed/refractory (R/R) FL. The discussion was led by Krish Patel, MD; perspectives and insights on current treatment options, trial data, and other novel therapies were exchanged.

ON SEPTEMBER 11, 2022, OncLive® brought together medical oncologists who specialize in the treatment of non–small cell lung cancer (NSCLC). Moderated by Grace K. Dy, MD, the objectives of the workshop were to evaluate the potential role and impact of new antibody-drug conjugates (ADCs) in the treatment of patients with NSCLC.